The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...

It has some rivals in its push to the IgG4-RD market, notably Amgen which reported positive topline results from a phase 3 trial of its CD19-directed antibody Uplizna (inebilizumab), acquired as ...